Unknown NA INTERVENTIONAL 1-arm NCT05823402

Use of SPECT-CT for Comparison of Dosimetry Methods in PSMA-targeted Radioligand Therapy (SPECTacular Study) (SPECTacular)

Sponsor: BAMF Health

Conditions Metastatic Castration-resistant Prostate Cancer

Interventions SPECT/CT

Updated 5 times since 2023 Last updated: May 1, 2023 Started: May 1, 2023 Primary completion: Oct 31, 2024 Completion: Oct 31, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This NA trial investigates Metastatic Castration-resistant Prostate Cancer and is currently ongoing. BAMF Health leads this study, which shows 5 recorded versions since 2023 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

5 versions recorded

Jun 2025 — Present [monthly]

Unknown NA

Status: Recruiting → Unknown
Sep 2024 — Jun 2025 [monthly]

Recruiting NA
Jul 2024 — Sep 2024 [monthly]

Recruiting NA
Jun 2023 — Jul 2024 [monthly]

Recruiting NA
May 2023 — Jun 2023 [monthly]

Recruiting NA

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

BAMF Health

Data source: BAMF Health

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Grand Rapids, United States